HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.
Kelvin Chee Ling Tan, Speaker at Dermatology Conferences
Elegant Clinic SDN BHD, Malaysia
Title : Unique cases of using autologous hair follicular stem cells (AMT) in hair restoration for both male and female pattern hair loss in asian populations


Hair follicle autologous micrografting for Androgenetic Alopecia in both men (male pattern hair loss) and women (female pattern hair loss) is the next great promise in the regenerative approach to this condition. Autologous Micrografting is a one-surgical-time procedure that stands out for being fast, easy to perform, safe and effective. It consists of the extraction of autologous hair follicle micrografts that will be injected as a solution into the scalp of the patient in the same surgical time, with no harvesting or cell manipulation involved.To obtain viable tissue micrografts we used the innovative Rigenera® system, which allows the disaggregation of small biopsies into micrografts of 70-80 microns suspended in a solution. This technology has been used for regenerative treatments in different fields, such as skin rejuvenation, wound healing, cartilage degeneration, and androgenetic alopecia. In the latter, these micrografts come from skin biopsies with healthy hair follicles, and contain progenitor and stem cells (CD90+/CD105+/CD73+/Melanocyte progenitor cells, HFDMSC CD 44+, HFESC CD200+), extracellular matrix (ECM), and growth factors.When transferring micrografts to the wounded tissues, they will communicate with cells affected by disease. Through this signalling in which growth factors (TGF-beta 1, PDGF-AA, IGF-1, IGFBP- 6/3/2, EGF and bFGF), ECM components, progenitor and stem cells are involved, the cells in the wounded areas start to activate the regeneration process. These growth factors are known to activate Erk pathways, MARK pathways, EGF-receptor signalling pathways and some other cascades in inflammatory regulatory response.While PRP is a known method based on platelet-derived growth factors and is not a homologous tissue, in Autologous Micrografting, micrografts are viable clusters of cells that secrete trophic and immunomodulatory factors through an extended period. All these components come from a tissue that is homologous to the recipient, and the signalling can be more specific than in PRP. Thus, the effects of the Autologous Micrografting treatment encompass multiple targets of the hair follicle miniaturisation process. It helps increase ECM production, growth factors production, neo-angiogenesis, modulation of inflammation and tissue remodelling. This helps achieve a stop in hair loss, increase in hair thickness, and faster and better wound healing.

Audience Take Away Notes:

  • I will share my particular technique to perform autologous micrografting procedures for androgenetic alopecia patients.
  • I will share differential diagnosis advice on how to select optimal patients eligible for an autologous micrografting procedure, to improve the accuracy of the treatment’s success.
  • Address best practices on Autologous Micrografting combination with other treatments, such as Hair Transplant, PRP, Minoxidil, Finasteride, Saw Palmetto, and how to perform it to achieve a synergetic effect.


Dr. Kelvin Tan was raised in Auckland, New Zealand where he graduated from high school and college. He obtained his Medical Degree (MBBS) from Kasturba Medical College in 2007, where is specialized in Hair Restoration and Hair line reconstruction. Then he pursued further Fellowship and Board Certification in Anti-Aging & Regenerative Medicine in the USA and other Aesthetic Medicine Qualifications in USA & South Korea. Dr. Kelvin is currently the Founder and Medical Director of Elegant Clinic Malaysia and has been practising medicine since 2008. He has worked as an Independent Consultant and Aesthetic Physician at Dermatology Centre for 4 and a half years, at Mahkota Medical Centre, a Multidisciplinary Specialist Hospital in the southern city of Melaka, Malaysia. He is also the Future Leader for Juvederm, Allergan Medical Institute (AMI).